Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.

Finally, highly significant reductions in insulin doses achieved in some patients may have led certain participants or caregivers to believe they were effectively unblinded during the study, introducing behavioral biases that could have impacted the results given the small numbers of patients enrolled in this study.

also in 132,142 other papers

The changes from baseline at lunch and dinner were numerically lower for sotagliflozin than placebo but did not reach statistical significance.

also in 111,027 other papers